Creative Touch Permanent Makeup and Aesthetics

Staphylococcus epidermidis is the most abundant commensal on most human skin surfaces, and its reclassification from “conditional pathogen” to “active commensal” is one of the most significant conceptual shifts in skin microbiome research over the past decade. In healthy skin, it contributes directly to barrier lipid synthesis through a secreted sphingomyelinase that converts host sphingomyelin into ceramides; reinforces antimicrobial defence by priming keratinocytes via TLR2 to produce β-defensin-2 and β-defensin-3 whilst simultaneously inducing A20 to prevent NF-κB overstimulation; competes with S. aureus through multiple secreted antagonists including the Esp serine protease, 6-thioguanine, phenol-soluble modulins, and lantibiotics; and trains both innate and adaptive immune responses in ways that generate long-lasting tolerance and barrier-specific surveillance. It is also one of the most important organisms for understanding skin dysbiosis: its decline under alkaline conditions, antibiotic pressure, or inflammatory cytokine suppression removes protective mechanisms that are not easily replaced. Its therapeutic role as a live biotherapeutic is actively entering clinical development.

Staphylococcus epidermidis occupies a paradoxical position in dermatology. As a coagulase-negative staphylococcus (CoNS), it has historically generated clinical concern primarily as a cause of device-associated infections in immunocompromised patients and a coloniser of implanted hardware. On healthy skin, however, it is the organism against which every other aspect of the skin’s microbial ecology operates – a keystone commensal whose removal reveals, by negative space, how many of the skin’s protective functions depend on its presence. ^[7]

The Organism and Its Distribution

S. epidermidis colonises all body surface sites, with density and proportion varying by microenvironment. It dominates dry skin sites (forearm, leg, back) where it constitutes the majority of culturable bacteria, is abundant at sebaceous sites alongside C. acnes, and maintains significant population at moist areas including the antecubital and popliteal fossae. It tolerates the acidic, low-moisture, high-salt environment of the stratum corneum – conditions that suppress many organisms – and is among the few residents adapted to thrive within the acid mantle’s functional pH range of approximately 4.5–5.5. ^[7]

Its genus-level identification masks significant strain heterogeneity. S. epidermidis agr quorum-sensing system type is one of the most clinically important distinctions: Type I and Type IV strains suppress S. aureus virulence factor expression and are associated with commensal skin phenotypes; Type II and III strains show hospital-environment adaptation tendencies and are associated with opportunistic pathogenesis. This heterogeneity means that “S. epidermidis” on a laboratory report is insufficient information – it is a species containing both the skin’s most valuable commensal allies and some of its most troublesome device colonisers, distinguished by genomic and quorum-sensing characteristics that standard culture cannot resolve. ^[5]

Ceramide Synthesis: The Sphingomyelinase Mechanism

The most direct structural contribution of S. epidermidis to the skin barrier is the secretion of a neutral sphingomyelinase – encoded by the sph gene – that cleaves sphingomyelin on the skin surface and in keratinocyte membranes, releasing ceramide. The mechanism is mutualistic in the literal sense: S. epidermidis acquires nutritional phosphocholine as a substrate, and the host receives an additional ceramide source it would not otherwise have at that location. ^[11]

The sph gene is present and expressed in the majority of S. epidermidis strains, including under experimental colonisation conditions and in the human skin microbiome in vivo. Critically, sphingomyelinase activity appears to be limited to S. epidermidis among the major skin-colonising bacteria tested – not observed at comparable levels in Corynebacterium, C. acnes, or other dominant staphylococci. In mouse models, wild-type S. epidermidis significantly increases skin ceramide levels and prevents water loss in barrier-disrupted skin in a manner entirely dependent on the Sph enzyme; sphingomyelinase-deficient mutants lose this protective effect. ^[11]

This has a direct clinical implication: the ceramide-supportive capacity of the skin’s barrier is, in part, microbially derived and not solely a product of endogenous keratinocyte synthesis. In dysbiotic skin where S. epidermidis populations are suppressed – by elevated pH, antibiotic pressure, or inflammatory cytokines – this external ceramide contribution is removed at the same time as the keratinocyte synthesis pathway is being suppressed by Th2 cytokine signalling. The ceramide deficit in atopic and dysbiotic skin is therefore both endogenous and exogenous in origin.

The ceramide–microbiome relationship is bidirectional in ways the one-directional sphingomyelinase model does not fully capture. A 2026 double-blind study found that topical ceramide application not only replenished barrier lipids but also improved microbiome diversity scores – suggesting that the lipid environment the barrier provides is itself part of the habitat that sustains S. epidermidis populations. ^[2] The mutualism therefore operates in both directions: S. epidermidis contributes ceramide synthesis capacity to the barrier, and a ceramide-replete barrier environment maintains the conditions in which S. epidermidis can persist. This feedback loop has a direct implication for dysbiotic skin: topical ceramide application is not only compensating for a lost lipid; it is partially restoring the habitat the organism that normally generates that lipid requires to re-establish.

TLR2 Signalling: Calibrated Immunity, Not Alarm

S. epidermidis communicates with keratinocytes primarily through TLR2 recognition of its lipoteichoic acid (LTA) and lipopeptide components. This activates NF-κB and drives expression of hBD-2 and hBD-3, the β-defensins with significant activity against S. aureus, Streptococcus pyogenes, and other potential pathogens. The magnitude of the NF-κB response to S. epidermidis is calibrated through induction of A20 (TNFAIP3), a deubiquitinase that limits NF-κB activation, enabling targeted hBD-2/hBD-3 production without generating the runaway inflammatory response that S. aureus TLR2 stimulation triggers. ^[3]

The practical consequence of this calibrated signalling is that S. epidermidis acts as an ongoing low-level immune primer – keeping the skin’s antimicrobial peptide baseline elevated without generating inflammatory pathology. Germ-free skin, without this priming, shows reduced AMP expression and greater vulnerability to challenge with pathogens. ^[10]

A separately identified lipopeptide, LP78, produced by S. epidermidis specifically represses TLR3-mediated inflammatory signalling, reducing TNF-α and IL-6 in response to skin injury. This is distinct from the TLR2-mediated AMP priming mechanism and represents an additional anti-inflammatory channel operating through a different receptor. ^[5]

The TLR2-driven AMP pathway gains additional clinical significance when considered alongside the vitamin D/VDR axis. S. epidermidis colonisation supports LL-37 production in keratinocytes alongside the primary VDR/calcitriol driver – the two signals sustaining antimicrobial peptide output through independent upstream routes. When S. epidermidis populations are suppressed by dysbiosis, elevated pH, or antibiotic pressure, the commensal contribution to LL-37 is removed. If the same client is also vitamin D deficient, the calcitriol/CAMP pathway provides no compensatory baseline. The LL-37 deficit becomes compounded from two mechanistically independent directions, neither of which is visible in the other’s clinical assessment. This convergence is particularly relevant in post-procedure recovery and in atopic presentations where both variables are commonly compromised together.

Acid Mantle Contribution

Beyond ceramide synthesis, S. epidermidis contributes to skin surface acidification through two metabolic routes. First, it ferments glycerol – a natural skin surface component present in sebum and eccrine secretions – producing lactic acid, acetic acid, and succinic acid. This organic acid production directly acidifies the local microenvironment, contributing to the maintenance of the upper stratum corneum’s pH in the range hospitable to commensals and inhibitory to S. aureus. Second, its lipase activity hydrolyses sebum components, generating short-chain fatty acids that independently acidify the surface. ^[4]

The S. aureus sensitivity to this acidification is specifically documented: S. aureus growth is inhibited in media supplemented with lactic acid at pH 4.8, and the Agr quorum-sensing regulator that controls S. aureus toxin expression is suppressed in the acidic, lactic-acid-replete environments that S. epidermidis metabolism helps maintain. The relationship is therefore not only competitive in the direct antibiotic sense – it is ecological, in that S. epidermidis metabolic activity maintains the chemical environment in which S. aureus cannot reach the quorum activation threshold. ^[1]

Direct S. aureus Antagonism: A Multi-Weapon Arsenal

S. epidermidis produces an unusually diverse array of compounds that directly suppress S. aureus. Their variety reflects long-term co-evolution between these two organisms across the same ecological niche:

• Esp (GluSE): A serine protease that degrades proteins critical for S. aureus biofilm formation and host epithelial adhesion. Epidemiological studies demonstrate that Esp-secreting S. epidermidis presence in nasal cavities correlates inversely with S. aureus colonisation in human volunteers – in vivo functional competition, not only in vitro activity. ^[5]

• 6-Thioguanine (6-TG): A purine analogue that suppresses S. aureus growth by inhibiting purine biosynthesis and – critically – toxin production. Toxin suppression without organism elimination reduces virulence without creating the selection pressure that drives resistance. ^[5]

• Phenol-soluble modulins (PSMγ, PSMδ): S. epidermidis PSMs synergise with the host antimicrobial peptide LL-37 to produce enhanced killing of S. aureus and Group A Streptococcus that neither achieves alone. PSMγ has been detected in the epidermis and dermis of normal human skin, confirming that this synergy operates in vivo under physiological conditions. ^[10]

• Lantibiotics (epilancin A37, Pep5, epifadin): Epilancin A37 selectively inhibits Corynebacterium competitors; Pep5 shows potent activity against S. aureus; epifadin disrupts bacterial membranes through a non-ribosomal synthesis pathway. ^[5]

• Agr interference: S. epidermidis AIP-I and multiple AIPs from related S. hominis inhibit the S. aureus agr quorum-sensing system, reducing toxin expression – a competitive mechanism that directly targets the virulence activation switch rather than the organism itself. ^[10]

This arsenal means that the loss of S. epidermidis from a dysbiotic skin community is not simply the loss of a beneficial organism – it is the simultaneous removal of multiple independent mechanisms for controlling S. aureus population density and virulence factor expression.

Immune Training: From Neonatal Tolerance to Adult Surveillance

S. epidermidis has a uniquely important role in early-life immune programming. Neonatal colonisation – occurring within days of birth – establishes S. epidermidis-specific regulatory T cell (Treg) populations in skin that create long-lasting tolerance to commensal antigens. This tolerance is window-dependent: colonisation during neonatal life establishes immune tolerance; colonisation in adult life does not generate the same effect. The clinical relevance is significant – disrupted commensal exposure in the neonatal window may contribute to lifelong inflammatory skin susceptibility, based on neonatal mouse colonisation models. ^[6]

In adult skin, S. epidermidis primes multiple immune cell populations that contribute to ongoing barrier surveillance:

• CD11B+ dendritic cells, stimulated by S. epidermidis, induce IL-17A+ CD8+ T cell homing to the epidermis – positioning cytotoxic T cells specifically at the barrier interface where S. aureus challenge is most likely to arise. ^[5]
• MAIT cells are activated by MR1-presented riboflavin metabolites from S. epidermidis, generating IL-17A production and contributing to mucosal-type antimicrobial defence in skin. ^[10]
• γδ T cells are activated by S. epidermidis-derived signals, including induction of perforin-2 in γδ T cells – an antimicrobial protein that kills intracellular bacteria and whose upregulation has been confirmed to correlate with enhanced S. aureus intracellular killing in skin tissue ex vivo. ^[5]

Wound Healing Contributions

S. epidermidis contributes to wound healing through mechanisms that operate across all three phases of repair. In the inflammatory phase, it stimulates CXCL10 expression in neutrophils, which recruits plasmacytoid dendritic cells (pDCs) and drives type I interferon production – a cascade that activates macrophages and fibroblasts to produce FGF2, FGF7, TGF-β1, and VEGF, accelerating the transition from inflammatory to proliferative phase. ^[8]

In the proliferative phase, S. epidermidis strains expressing the SadA enzyme convert aromatic amino acids into trace amines, which suppress β2-adrenergic receptor inhibition of keratinocyte migration – directly accelerating re-epithelialisation. S. epidermidis-specific CD8+ T cells induced through non-classical MHC-Ib antigen presentation acquire a tissue-repair phenotype, producing IL-13, AREG, FGF7, and FGF10 – growth factors that coordinate epithelial regeneration. ^[9]

These findings have direct relevance for post-procedure wound management: skin that enters a treatment in a dysbiotic state – with depleted S. epidermidis and elevated S. aureus – does so with reduced innate capacity to recruit the repair-phase immune signals that S. epidermidis normally provides.

The Dual-Nature Caveat

S. epidermidis remains a leading cause of device-associated infection, particularly in immunocompromised patients, and the frequency of methicillin-resistant S. epidermidis (MRSE) strains in hospital environments is increasing. Its capacity for biofilm formation on implanted hardware creates infection states that are difficult to treat precisely because the biofilm architecture confers the same mechanical protection against host immunity and antimicrobials that makes it an effective commensal on skin surfaces. This dual nature is strain-specific and context-specific – the same species that sustains barrier health in healthy skin under low-pH, nutrient-limited conditions can become an opportunistic pathogen when host immunity is suppressed, barrier integrity is lost, or the organism encounters an implanted foreign body. ^[5]